CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Skeletal Muscle

Table 2 No difference was observed in the relative numbers of circulating CD4⁺ and CD8⁺ T cell subsets expressing high densities of CD49d in patients with IBM and healthy controls

T cell subpopulation	Relative cell number (mean ± SD)^a		p value	Number of individuals
T cell subpopulation	Healthy	IBM	p value	Healthy	IBM
CD4⁺CD49d^hi	35.24 ± 13.10	34.23 ± 18.25	0.44	21	23
CD8⁺CD49d^hi	44.89 ± 14.66	43.92 ± 14.59	0.60	17	20

^aData are presented as relative cell numbers of T cell subsets expressing high levels of the CD49d integrin subunit. No significant differences (p > 0.05) were seen in both T cell subpopulations when healthy patients were compared to IBM individuals

ISSN: 2044-5040